Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

85P - Focus on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A real-world retrospective analysis

Date

27 Jun 2024

Session

Poster Display session

Presenters

Maria Alessandra Calegari

Citation

Annals of Oncology (2024) 35 (suppl_1): S1-S74. 10.1016/annonc/annonc1477

Authors

M.A. Calegari1, V. Formica2, F. Zoratto3, G. Arrivi4, A. Torsello5, M. Polito6, V. Picone7, A. Emiliani8, V. Cereda9, M. Schirripa10, G. Caira11, A. Spring11, G. Valente11, C. Morelli2, M. Rofei2, C. Spoto3, F. Mazzuca12, A. Artemi13, E. Dell'Aquila14, L. Salvatore1

Author affiliations

  • 1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome/IT
  • 2 Policlinico Tor Vergata, Rome/IT
  • 3 Ospedale Santa Maria Goretti - ASL Latina, Latina/IT
  • 4 Azienda Ospedaliera Sant'Andrea, Rome/IT
  • 5 Ospedale San Giovanni, Rome/IT
  • 6 Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma/IT
  • 7 Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, Rome/IT
  • 8 Isola Tiberina Hospital, Gemelli Isola, Rome/IT
  • 9 ASL Roma 4, Ospedale Padre Pio, Bracciano, Bracciano/IT
  • 10 Ospedale Belcolle - ASL Viterbo, Viterbo/IT
  • 11 Fondazione Policlinico Universitario Agostino Gemelli–IRCCS, Università Cattolica del Sacro Cuore, Rome/IT
  • 12 Azienda Ospedaliero-Universitaria Sant'Andrea - Università Sapienza di Roma, Rome/IT
  • 13 IRCCS REGINA ELENA NATIONAL CANCER INSTITUTE, Rome/IT
  • 14 IRCCS Regina Elena National Cancer Institute, IT-00128 - Rome/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 85P

Background

HER2+ mCRCs, displaying HER2 overexpression or ERBB2 amplification, represent a rare molecular subset, accounting for 2- 6%. Recently, its role as a potential actionable target has emerged, with promising results in refractory mCRC. Despite that, nowadays HER2 testing is not routinely included in the diagnostic workup of mCRC.

Methods

This is an observational, retrospective, multicenter study, aiming to describe features and prognostic value of HER2+ mCRCs from real world pts. Pts with mCRC tested for HER2 status who received at least one line of therapy (tx) at 11 Italian Institutions within the Lazio Region between Mar2011 and Jan2024 were enrolled. HER2 status was assessed either for HER2 overexpression using IHC according to the HERACLES diagnostic criteria or for ERBB2 amplification using NGS. Differences between groups were compared using the Chi Square test. Endpoint for prognostic assessment was OS. Endpoints for predictive assessment were PFS, RR and DCR. Statistical significance was set at p .05.

Results

495 pts were included, of those 57 pts had a HER2+ mCRC (11.5%). HER2 positivity was more frequent among tumors with RASwt compared to RASmt (14.6 vs 8.5%; p .03), lung mts (p .04), synchronous metastatic disease (p .03), lymph node mts (p.02), brain mts (p.01) and liver mts (p.004). No correlation with primary tumor location (PTL) was observed (p .2). At a median FU of 19.2 months, OS did not significantly differ according to HER2 (p .1). 127 pts with RASwt mCRC (109 HER2- and 18 HER2+) received an antiEGFR-based first-line tx. PFS was significantly shorter (p .01) and RR was lower for HER2+ tumors (p .003), while no difference was observed for DCR (p .3). Of 57 HER2+ tumors, 12 received an antiHER2 tx (9 were RASwt and 3 RASmt), with RAS status not significantly impacting on antiHER2 activity.

Conclusions

We showed that HER2+ mCRCs are more frequently, though not exclusively, RASwt, and display a specific mts tropism. No association with PTL was observed. HER2 does not impact on prognosis while confirms as negative predictor for antiEGFR tx. Target actionability seems to be retained irrespective of RAS status. The baseline molecular workup of mCRC must include HER2 assessment, irrespective of RAS mutational status and primary tumor location.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.